Centessa Pharmaceuticals (NASDAQ:CNTA) Stock Price Down 5.3% Following Insider Selling

Centessa Pharmaceuticals plc (NASDAQ:CNTA) shares fell 5.3% during trading on Monday after an insider sold shares in the company. The company traded as low as $17.85 and last traded at $18.02. 142,969 shares changed hands during trading, a decline of 77% from the average session volume of 617,110 shares. The stock had previously closed at $19.03.

Specifically, insider Karen M. Anderson sold 30,526 shares of Centessa Pharmaceuticals stock in a transaction on Friday, February 7th. The stock was sold at an average price of $19.03, for a total value of $580,909.78. Following the completion of the sale, the insider now owns 54,322 shares of the company’s stock, valued at $1,033,747.66. The trade was a 35.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CTO Tia L. Bush sold 11,000 shares of the stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $16.86, for a total value of $185,460.00. Following the completion of the transaction, the chief technology officer now directly owns 121,503 shares in the company, valued at approximately $2,048,540.58. This represents a 8.30 % decrease in their position. The disclosure for this sale can be found here. In related news, insider Karen M. Anderson sold 6,471 shares of the firm’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $16.86, for a total value of $109,101.06. Following the transaction, the insider now owns 54,322 shares of the company’s stock, valued at approximately $915,868.92. This trade represents a 10.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Wall Street Analyst Weigh In

Several research firms have weighed in on CNTA. Guggenheim reiterated a “buy” rating on shares of Centessa Pharmaceuticals in a research report on Monday. TD Cowen started coverage on Centessa Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating on the stock. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $25.83.

Centessa Pharmaceuticals Stock Down 3.0 %

The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The stock has a 50 day simple moving average of $16.78 and a 200-day simple moving average of $15.54.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.05. Analysts expect that Centessa Pharmaceuticals plc will post -1.6 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Centessa Pharmaceuticals by 47.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock worth $40,000 after buying an additional 826 shares in the last quarter. GAMMA Investing LLC increased its holdings in Centessa Pharmaceuticals by 103.1% in the 3rd quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock valued at $48,000 after acquiring an additional 1,509 shares during the last quarter. Walleye Capital LLC bought a new stake in Centessa Pharmaceuticals in the 3rd quarter valued at $187,000. China Universal Asset Management Co. Ltd. lifted its stake in Centessa Pharmaceuticals by 99.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,593 shares of the company’s stock worth $217,000 after purchasing an additional 6,785 shares in the last quarter. Finally, Harbour Capital Advisors LLC bought a new position in shares of Centessa Pharmaceuticals during the 3rd quarter valued at about $259,000. 82.01% of the stock is currently owned by institutional investors.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.